

Nonsense suppression activity of PTC124 (ataluren)

Auld et al. (1) suggest that PTC124's nonsense suppression activity may be an indirect consequence of the compound's effects on firefly luciferase (FLuc) enzymatic activity. However, our initial characterization of potential nonsense-suppressing compounds in FLuc assays also utilized independent assays of nonsense suppression in disease-relevant




Fig. 1. PTC124 luciferase inhibition varies depending on the luciferase substrate used in the assay. (A) Inhibition of luciferase enzymatic activity is substrate-dependent. Recombinant luciferase protein (Sigma) was incubated with the indicated concentrations of PTC124 (synthesized by PTC Therapeutics). Luminescence was determined by using either the Bright-Glo or Steady-Glo luciferase substrate (Promega) as described by the manufacturer, and monitored with a Viewlux CCD imager (Perkin-Elmer). Luminescence data were normalized to reactions containing solvent alone (DMSO) and the percentage luciferase inhibition was calculated. Dotted line: 50% inhibition. (B) Inhibition of luciferase activity in the cell-based nonsense suppression assay is substrate-dependent. 293H cells were transiently transfected with a LUC nonsense suppression reporter gene containing a premature UGA terminator at codon 190 (2) and treated with the indicated concentrations of PTC124 for 20 h. After incubation, luminescence was determined by using either the Bright-Glo or Steady-Glo luciferase substrate as described for A. Luciferase activities were normalized to that produced with solvent alone (DMSO), and the fold suppression over background was calculated as $\text{PTC124}_{\text{light units}}/\text{DMSO}_{\text{light units}}$.

systems, including assays measuring synthesis of full-length protein in mdx myotubes, mdx mice, and *Cftr*^{-/-} transgenic mice (2, 3). These tests eliminated inactive chemical scaffolds and identified PTC124. Subsequently, PTC124 demonstrated nonsense suppression activity in cystic fibrosis and Duchenne muscular dystrophy patients (2, 4). These independent confirmations in validated suppression assays are to be contrasted with Auld et al.'s (1) use of a Renilla luciferase reporter that was an unsuitable and misinterpreted gauge of nonsense suppression because it failed to respond appreciably to the established nonsense-suppressing aminoglycoside, G418.

Although Auld and colleagues demonstrated elsewhere (5, 6) that luciferase IC₅₀ activities vary widely with different luciferase substrates, in their recent PNAS article they presented only data from the Steady-Glo substrate (1). However, Steady-Glo has a 60-fold lower IC₅₀ for PTC124 than Bright-Glo, the substrate we used (2) (Fig. 1A). Detection of nonsense suppression at 30 nM PTC124, well below the IC₅₀ value of Bright-Glo, indicates that the FLuc suppression activity we reported (2) cannot be due to enzyme inhibition. Auld et al. (1) also utilized transient transfections, whereas we used stable cell lines (2). Using transient transfections and both FLuc substrates, we found that PTC124 treatment recapitulated our previously reported Bright-Glo results (2) (Fig. 1B). However, consistent with the potent PTC124 IC₅₀ with Steady-Glo, no luciferase activity was observed at any concentrations tested (Fig. 1B).

PTC124's activity in animal models and clinical trials, and the failure of Auld et al. (1) to replicate our assay conditions, indicates that their study is not relevant to the nonsense suppression efficacy of PTC124.

Stuart W. Peltz^{a,1}, Ellen M. Welch^a, Allan Jacobson^b, Christopher R. Trotta^a, Nikolai Naryshkin^a, H. Lee Sweeney^c, and David M. Bedwell^d
^aPTC Therapeutics, Inc., 100 Corporate Court, South Plainfield, NJ 07080; ^bDepartment of Molecular Genetics and Microbiology, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655; ^cDepartment of Physiology, University of Pennsylvania School of Medicine, 3700 Hamilton Walk, Philadelphia, PA 19104; and ^dDepartment of Microbiology and Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL 35294

1. Auld DS, Thorne N, Maguire WF, Inglese J (2009) Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression. *Proc Natl Acad Sci USA* 106:3585–3590.
2. Welch EM, et al. (2007) PTC124 targets genetic disorders caused by nonsense mutations. *Nature* 447:87–91.
3. Du M, et al. (2008) PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. *Proc Natl Acad Sci USA* 105:2064–2069.
4. Kerem E, et al. (2008) Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: A prospective phase II trial. *Lancet* 372:719–727.
5. Auld, DS, et al. (2008) Characterization of chemical libraries for luciferase inhibitory activity. *J Med Chem* 51:2372–2386.

Author contributions: S.W.P., E.M.W., A.J., C.R.T., N.N., L.L.S., and D.M.B. wrote the paper.

Conflict of interest statement: S.W.P., E.M.W., A.J., C.R.T., N.N., L.L.S., and D.M.B. are employees or consultants of PTC Therapeutics, Inc.

¹To whom correspondence should be addressed. E-mail: speltz@ptcbio.com.